Biohaven Ltd.
BHVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBiohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. Valued at $2.32B, BHVN is a mid-cap name in its sector. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Market Cap
$2.32B
Beta
3.14
P/E (TTM)
—
P/E (Fwd)
-7.92
EPS (TTM)
$-6.07
EPS (Fwd)
$-1.95
ROE
-333.0%
ROA
-83.4%
Cash
$347.8M
Total Debt
$286.2M
Free CF
-$379.4M
52W Change
9.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $347.8M in cash comfortably exceeding the $286.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$379.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -333.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Biohaven Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing BHVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.